Mangrove Partners’s Caris Life Sciences CAI Stock Holding History

Mangrove Partners’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-42,483	Closed	-$1.15M	–	624
2025 Q4	$1.15M	Buy	+42,483	New	+$1.2M	0.09%	81

Other funds holding CAI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHWEPV

J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM

SSP

Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mangrove Partners's CAI Position: Q1 2026 in Review

Mangrove Partners sold out of Caris Life Sciences (CAI) in Q1 2026, closing a stake of 42,483 shares — an estimated $1.15M sold.

Mangrove Partners first reported a position in CAI in Q4 2025 and held it in 1 quarter. The position peaked at $1.15M in Q4 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

Mangrove Partners reported no remaining Caris Life Sciences position as of Q1 2026 after selling out during the quarter.
Mangrove Partners sold 42,483 Caris Life Sciences shares in Q1 2026, an estimated $1.15M.
Mangrove Partners first reported a position in Caris Life Sciences in Q4 2025 and held it in 1 quarter.
Mangrove Partners's Caris Life Sciences position peaked at $1.15M in Q4 2025.
202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.